Why the study?
Does liraglutide prevent major adverse cardiovascular events in patients in phase 2 and 3 clinical trials?
Population
6,638 patients from 15 completed phase 2 and 3 studies in the liraglutide clinical development programme
Comparison
Liraglutide (n=4,257) vs All comparator drugs
Design
Meta-analysis
Authors
Loading...
Acceptable MACE safety with liraglutide in pooled phase 2/3 data; confirms FDA regulatory compliance for diabetes therapies.
Does liraglutide prevent major adverse cardiovascular events in patients in phase 2 and 3 clinical trials?
In a patient-level pooled analysis of phase 2 and 3 trials, liraglutide demonstrated an acceptable cardiovascular safety profile that falls within FDA regulatory limits for diabetes therapies.
Marso et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: